Latest news

• ViiV builds case for switching to its two-drug HIV combinations

  That is a concern which some suggest has been behind the relatively slow take-up of Juluca since its launch. ... For comparison, Biktarvy brought in $739m in sales in the first quarter of the year, compared to $70m for Juluca in the second-line setting.

• ViiV bags EU okay for new two-drug HIV therapy

  Dovato is the second two-drug combination to be introduced by the company after Juluca (dolutegravir/rilpivirine), which is approved for use in patients a second-line option for patients who ... Juluca struggled to make much headway with sales running at

• Shingrix lifts GSK in Q1, but two more vaccines are culled

  GSK is looking to a series of new two-drug HIV drugs to inject new momentum in the HIV franchise, and the first of these – Juluca (dolutegravir/rilpivirine) – added £70m in ... ViiV chairman David Redfern said Juluca and Dovato – alongside

• Dovato approval key for Glaxo in HIV treatment

  ViiV already have another two-in-one STR, Juluca (dolutegravir/rilpivirine), but this is only approved for HIV patients who have achieved viral suppression with another antiretroviral therapy. ... Recent studies have set Juluca up to be a strong

• Gilead awaits CEO and readouts to revive fortunes

  Gilead’s new drug is facing competition from GSK’s new arrival in HIV, Juluca.